Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-658-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.61 million
Profitability
Miscellaneous
Employees154
OptionableOptionable
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.09. The business earned $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. Karyopharm Therapeutics had a negative net margin of 502.90% and a negative return on equity of 104.50%. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
11 brokers have issued 12 month price targets for Karyopharm Therapeutics' stock. Their predictions range from $18.00 to $30.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $23.1111 in the next year. This suggests a possible upside of 134.4% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.
What is the consensus analysts' recommendation for Karyopharm Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We continue to believe that selinexor could be approved for use in r/ r DLBCL patients, and we are encouraged by the data." (12/3/2018)
- 3. Cantor Fitzgerald analysts commented, "KPTI reported top-line STORM data, which demonstrated a 25.4% ORR (2 CRs and 19 PRs) and 4.4 months DoR in penta-refractory myeloma patients. That means the company will be able to file an NDA for accelerated approval in this population in the U.S. and Europe." (4/30/2018)
Has Karyopharm Therapeutics been receiving favorable news coverage?
News coverage about KPTI stock has trended very positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news impact score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Insmed (INSM) and Madrigal Pharmaceuticals (MDGL).
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
- Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
- Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
- Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 60)
Who are Karyopharm Therapeutics' major shareholders?
Karyopharm Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Private Capital Advisors Inc. (0.73%) and First Midwest Bank Trust Division (0.28%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.
Which institutional investors are selling Karyopharm Therapeutics stock?
KPTI stock was sold by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.
Which institutional investors are buying Karyopharm Therapeutics stock?
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $9.86.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $598.58 million and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.
What is Karyopharm Therapeutics' official website?
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
